



## SOTA24 Faculty Disclosures Word

The following types of relationships may be deemed relevant include:

1. Advisor or Review Panel Member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/Research Support
6. Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)
7. Independent Contractor
8. Ownership Interest
9. Royalties
10. Intellectual Property/Patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Other Financial or Material Support

*All of the relevant financial relationships listed for the meeting faculty have been mitigated.*

### **Annapureddy, Narender, MD, MS**

Challenging Cases in RA: Joints and Beyond

Role: Moderator

Digital Ischemia for the Rheumatologist

Role: Moderator

Integrative Rheumatoid Arthritis Treatment Guidelines

Role: Moderator

Disclosure: AURINIA, 1 (Terminated, August 10, 2023); GlaxoSmithKlein(GSK), 2 (Ongoing);

Novartis, 1 (Terminated, July 29, 2022)

### **Bass, Anne, MD**

Checkpoint Inhibitor Complications of the Rheumatologists

Role: Speaker

Checkpoint Inhibitor Complications of the Rheumatologists

Role: Speaker

Cocktail and Cases

Role: Roundtable Participant

Vaccination Guideline Updates

Role: Speaker

Vaccination Guideline Updates

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Bridges, S. Louis, MD, PhD**

Exploring the Role of Artificial Intelligence in the Future of Rheumatoid Arthritis Management

Role: Speaker

Exploring the Role of Artificial Intelligence in the Future of Rheumatoid Arthritis Management

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Bunyard, Matthew, MD, RhMSUS**

Challenging Cases in Fibromyalgia and Chronic Pain: An Update for the Rheumatologist

Role: Moderator

Challenging Cases in Sjogren's Syndrome: Beyond the Dryness

Role: Moderator

CPPD Update: Let's Be Crystal Clear

Role: Moderator

Disclosure: No financial relationships with ineligible companies to disclose

**Byram, Kevin, MD**

Checkpoint Inhibitor Complications of the Rheumatologists

Role: Moderator

Hypermobility Syndromes

Role: Moderator

Lung Disease in Scleroderma

Role: Moderator

Disclosure: Hemoshear Therapeutics, 2 (Terminated, August 10, 2023)

**Dawn, Pedrotty, MD, PhD**

Cardiac Sarcoidosis for the Rheumatologist

Role: Speaker

Cardiac Sarcoidosis for the Rheumatologist

Role: Speaker

Cocktail and Cases

Role: Roundtable Participant

Disclosure: No financial relationships with ineligible companies to disclose

**Ferrada, Marcela, MD**

Cocktail and Cases

Role: Roundtable Participant

VEXAS Syndrome: Still Vexing Rheumatologists?

Role: Speaker

VEXAS Syndrome: Still Vexing Rheumatologists?

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Ferreira, Carlos**

SOTA Committee

Role: Staff

Disclosure: No financial relationships with ineligible companies to disclose

**Frech, Tracy, MD, MS**

Cocktail and Cases

Role: Roundtable Participant  
Digital Ischemia for the Rheumatologist  
Role: Speaker  
Digital Ischemia for the Rheumatologist  
Role: Speaker  
Disclosure: No financial relationships with ineligible companies to disclose

**Grissom, Robert L., MD**

Challenging Cases in RA: Joints and Beyond  
Role: Presentation Contributor  
Disclosure: No financial relationships with ineligible companies to disclose

**Hassan, Sobia, MD, RhMSUS, MRCP**

Cardiac Sarcoidosis for the Rheumatologist  
Role: Moderator  
CAR-T Cell Therapy: What the Rheumatologists Need to Know  
Role: Moderator  
Cocktail and Cases  
Role: Speaker  
Neurosarcoidosis: The Great Mimicker  
Role: Moderator  
Opening Remarks  
Role: Speaker  
Disclosure: No financial relationships with ineligible companies to disclose

**Johr, Chadwick, MD**

Challenging Cases in Sjogren's Syndrome: Beyond the Dryness  
Role: Speaker  
Challenging Cases in Sjogren's Syndrome: Beyond the Dryness  
Role: Speaker  
Disclosure: Bristol-Myers Squibb(BMS), 1 (Ongoing), 2 (Ongoing)

**Khanna, Dinesh, MD, MSc**

Lung Disease in Scleroderma  
Role: Speaker  
Lung Disease in Scleroderma  
Role: Speaker  
Disclosure: Chemomab, 1 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing); Zuro Bio, 2 (Ongoing)

**Korn, Lisa, MD, PhD**

Behçet's Syndrome: An Update  
Role: Moderator  
VEXAS Syndrome: Still Vexing Rheumatologists?  
Role: Moderator  
Disclosure: No financial relationships with ineligible companies to disclose

**Kugasia, Aman, MD**

Exploring the Role of Artificial Intelligence in the Future of Rheumatoid Arthritis Management  
Role: Moderator

Vaccination Guideline Updates

Role: Moderator

Disclosure: No financial relationships with ineligible companies to disclose

**Malfait, Anne-Marie, MD, PhD**

Hypermobility Syndromes

Role: Speaker

Hypermobility Syndromes

Role: Speaker

Disclosure: Averitas, 2 (Ongoing)

**Minhas, Deeba, MD**

Challenging Cases in Fibromyalgia and Chronic Pain: An Update for the Rheumatologist

Role: Speaker

Challenging Cases in Fibromyalgia and Chronic Pain: An Update for the Rheumatologist

Role: Speaker

Cocktail and Cases

Role: Roundtable Participant

Disclosure: No financial relationships with ineligible companies to disclose

**Munoz, Javier**

CAR-T Cell Therapy: What the Rheumatologists Need to Know

Role: Speaker

CAR-T Cell Therapy: What the Rheumatologists Need to Know

Role: Speaker

Disclosure: No relevant disclosure to display

**O'Dell, James, MD**

Challenging Cases in RA: Joints and Beyond

Role: Speaker

Challenging Cases in RA: Joints and Beyond

Role: Speaker

Cocktail and Cases

Role: Roundtable Participant

Disclosure: No financial relationships with ineligible companies to disclose

**Sanchez-Claudio, Allison**

SOTA Committee

Role: Staff

Disclosure: No financial relationships with ineligible companies to disclose

**Smith, Benjamin, PA-C, DMSc**

Cocktail and Cases

Role: Roundtable Participant

Integrative Rheumatoid Arthritis Treatment Guidelines

Role: Speaker

Integrative Rheumatoid Arthritis Treatment Guidelines

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Tavee, Jinny, MD**

Cocktail and Cases

Role: Roundtable Participant

Neurosarcoidosis: The Great Mimicker

Role: Speaker

Neurosarcoidosis: The Great Mimicker

Role: Speaker

Disclosure: Argenyx, 1 (Terminated, September 10, 2022); CSL Behring, 2 (Ongoing); EBSCO, Topic editor (Dynamed) (Ongoing); Medlink, Author (Ongoing)

**Tedeschi, Sara, MD, MPH**

Cocktail and Cases

Role: Roundtable Participant

CPPD Update: Let's Be Crystal Clear

Role: Speaker

CPPD Update: Let's Be Crystal Clear

Role: Speaker

Disclosure: Avalo Therapeutics, 2 (Ongoing); Merck, 2 (Ongoing); Novartis, 2 (Terminated, December 19, 2022)

**Wise, Denisha**

SOTA Committee

Role: Staff

Disclosure: No financial relationships with ineligible companies to disclose

**Yazici, Yusuf, MD**

Behçet's Syndrome: An Update

Role: Speaker

Behçet's Syndrome: An Update

Role: Speaker

Cocktail and Cases

Role: Roundtable Participant

Disclosure: Amgen, 2 (Ongoing); Bristol-Myers Squibb(BMS), 2 (Ongoing), 5 (Ongoing); Chugai, 2 (Ongoing); Hemay, 2 (Ongoing); Soligenix, 2 (Ongoing)